Company: RCUS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001724521-25-000063
Chunk: 236

Company: Arcus Biosciences, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 236
---
imberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. Under this agreement, as of March 31, 2025, we may incur (i) regulatory milestone payments of up to $50 million for zimberelimab, and commercialization milestone payments of up to $375 million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.For the three months ended March 31, 2025 and 2024, we did not have any milestones or royalties due under this arrangement.WuXi Biologics License - anti-CD39In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under this arrangement. As of March 31, 2025, we may incur additional clinical and regulatory milestone payments of up to $14 million and royalty payments in the low single digits on net sales of the licensed products under this agreement. For the three months ended March 31, 2025 and 2024, we did not have any milestones or royalties due under this arrangement. Abmuno LicenseIn 2016, we entered into an agreement (the "Abmuno Agreement") with Abmuno Therapeutics LLC ("Abmuno"), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. Under this agreement, as of March 31, 2025 we may incur additional clinical, regulatory and commercialization milestone payments of up to $88 million.

10

For the three months ended March 31, 2025 and 2024, we did not have any milestones due under this arrangement.

Note 5. Revenues 

The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):Three Months Ended March 31,Over timePoint in time20252024Gilead collaboration    License and R&D services* $20 $131 R&D services*2 2 Access rights* 6 8 Taiho collaboration    Other*— 4 Total revenues  $28 $145 Total revenues from collaborations$20 $135 Total revenues from a customer$8 $10